QQ客服 官方微博 反馈留言

	Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study
	Qi, Fei; Wang, Wei-Hu; He, Xiao-Hui; Chen, Bo; Gui, Lin; Fang, Hui; Liu, Peng; Wang, Shu-Lian; Yang, Jian-Liang; Song, Yong-Wen
	2018
卷号	102期号:1页码:61-70
ISSN号	0360-3016
DOI	10.1016/j.ijrobp.2018.05.046
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6355762
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Qi, Fei,Wang, Wei-Hu,He, Xiao-Hui,et al. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study[J],2018,102(1):61-70.
APA	Qi, Fei.,Wang, Wei-Hu.,He, Xiao-Hui.,Chen, Bo.,Gui, Lin.,...&Dong, Mei.(2018).Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.,102(1),61-70.
MLA	Qi, Fei,et al."Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study".102.1(2018):61-70.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。